 All eligible patients will undergo coronary artery bypass grafting CABG and, in previously identified areas of viable, ischemic myocardium unsuitable for direct revascularization, be randomized to either placebo saline or intramyocardial injection of bone marrow-derived cells BMC during surgery. 